The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Nevzorova V.A.

Pacific State Medical University, Vladivostok, Russia

Kochetkova E.A.

Vladivostokskiĭ gosudarstvennyĭ meditsinskiĭ universitet

Ugaĭ L.G.

Vladivostokskiĭ gosudarstvennyĭ meditsinskiĭ universitet

Maistrovskaya Yu.V.

Pacific State Medical University, Ministry of Health of Russia, Vladivostok, Russia

Khludeeva E.A.

Pacific State Medical University, Ministry of Health of Russia, Vladivostok, Russia

Role of vascular remodeling markers in the development of osteoporosis in idiopathic pulmonary arterial hypertension

Authors:

Nevzorova V.A., Kochetkova E.A., Ugaĭ L.G., Maistrovskaya Yu.V., Khludeeva E.A.

More about the authors

Journal: Therapeutic Archive. 2016;88(9): 65‑70

Read: 2834 times


To cite this article:

Nevzorova VA, Kochetkova EA, Ugaĭ LG, Maistrovskaya YuV, Khludeeva EA. Role of vascular remodeling markers in the development of osteoporosis in idiopathic pulmonary arterial hypertension. Therapeutic Archive. 2016;88(9):65‑70. (In Russ.)
https://doi.org/10.17116/terarkh201688965-70

Recommended articles:
The condition of bone tissue in patients with non-alcoholic fatty liver disease. Russian Journal of Preventive Medi­cine. 2025;(5):82-89
Vertebroplasty for pathological vertebral fracture with osteoporosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(6):67-76
A contemporary view of athletic amenorrhea and its correction methods. (Literature review). Problems of Balneology, Physiotherapy and Exercise Therapy. 2025;(3):62-71
Musculoskeletal diso­rders in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(11-2):6-10

References:

  1. Wang TK, O'Sullivan S, Gamble GD, Ruygrok PN. Bone density in heart or lung transplant recipients - a longitudinal study. Transplant Proc. 2013;45(6):2357-2365. doi:10.1016/j.transproceed.2012.09.117
  2. 2016 Global Initiative for Chronic Obstructive Lung Disease (updated 2016). http://www.goldcopd.org/uploads/users/files/WatermarkedGlobal_20Strategy_202016(1).pdf
  3. 2015 GINA Report, Global Strategy for Asthma Management and Prevention. http://ginasthma.org/gina-report-global-strategy-for-asthma-management-and-prevention/
  4. Bon JM, Zhang Y, Duncan SR, Pilewski JM, Zaldonis D, Zeevi A, McCurry KR, Greenspan SL, Sciurba FC. Plasma inflammatory mediators associated with bone metabolism in COPD. COPD. 2010;7:186-191.  doi:10.3109/15412555.2010.482114
  5. Vrieze A, de Greef MH, Wijkstra PJ, Wempe JB. Low bone mineral density in COPD patients related to worse lung function, low weight and decreased fat-free mass. Osteoporos Int. 2007;18(9):1197-1202.
  6. Franco CB, Paz-Filho G, Gomes PE, Nascimento VB, Kulak CA, Boguszewski CL, Borba VZ (2009) Chronic obstructive pulmonary disease is associated with osteoporosis and low levels of vitamin D. Osteoporos Int. 2009;20:1881-1887. doi:10.1007/s00198-009-0890-5
  7. Katsura H, Kida K. A comparison of bone mineral density in elderly female patients with COPD and bronchial asthma. Chest. 2002;122:1949-1955.
  8. Martynuyk Т, Chasova I. New features in the treatment strategy of patients with idiopathic pulmonary hypertension: endothelin receptor antagonist bosentan. Sistemnye gipertensii. 2008;4:25-36. http://www.gipertonik.ru/files/journals/SG4(2008).pdf (In Russ.)
  9. Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37(1):67-119.  doi:10.1093/eurheartj/ehv317
  10. Tschopp O, Schmid C, Speich R, Seifert B, Russi EW, Boehler A. Pretransplantation bone disease in patients with primary pulmonary hypertension. Chest. 2006;129:1002-1008.
  11. Malik N, McCarthy K, Minai OA. Prevalence and significance of decreased bone density in pulmonary arterial hypertension. South Med J. 2012;105(7):344-349.  doi:10.1097/SMJ.0b013e31825b8117
  12. Peled N, Shitrit D, Fox BD, Shlomi D, Amital A, Bendayan D, Kramer MR. Peripheral arterial stiffness and endothelial dysfunction in idiopathic and scleroderma associated pulmonary arterial hypertension. J Rheumatol. 2009;36(5):970-975.  doi:10.3899/jrheum.081088
  13. Safdar Z, Tamez E, Frost A, Guffey D, Minard CG, Entman ML. Collagen Metabolism Biomarkers and Health Related Quality of Life in Pulmonary Arterial Hypertension. Int J Cardiovasc Res. 2015;4(2). doi:10.4172/2324-8602.1000198
  14. Alangiakrishman K, Juby A, Hanley D, Tymchak W, Sclater A. Role of vascular factors in osteoporosis. J Gerontol: Med Scie. 2003;58(4):362-366.
  15. Sumino H, Ichikawa S, Kasama S et al. Relationship between brachial arterial endothelial function and lumbar spine bone mineral density in postmenopausal women. Circulation J. 2007;71(10):1555-1559. doi:10.1253/circj.71.1555
  16. Prasad M, Reriani M, Khosla S, Gössl M, Lennon R, Gulati R, Prasad A, Lerman LO, Lerman A. Coronary microvascular endothelial dysfunction is an independent predictor of development of osteoporosis in postmenopausal women. Vasc Health Risk Manag. 2014;10:533-538.  doi:10.2147/VHRM.S63580
  17. Delgado-Frías E, López-Mejias R, Genre F, Ubilla B, Gómez Rodríguez-Bethencourt MA, González-Díaz A, de Vera-González AM, González-Rivero AF, Díaz-González F, González-Gay MA, Ferraz-Amaro I. Relationship between endothelial dysfunction and osteoprotegerin, vitamin D, and bone mineral density in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2015;33(2):241-249.
  18. Madonna R, Novo G, Balistreri CR. Cellular and molecular basis of the imbalance between vascular damage and repair in aging and age-related diseases: As biomarkers and targets for new treatments. Mech Ageing Dev. 2016 Mar 15. pii: S0047-6374(16)30026-4.  doi:10.1016/j.mad.2016.03.005
  19. Clarkin CE, Gerstenfeld LC. VEGF and bone cell signalling: an essential vessel for communication? Cell Biochem Funct. 2013;31(1):1-11.  doi:10.1002/cbf.2911
  20. Wang XM, Shi K, Li JJ, Chen TT, Guo YH, Liu YL, Yang YF, Yang S. Effects of angiotensin II intervention on MMP-2, MMP-9, TIMP-1, and collagen expression in rats with pulmonary hypertension. Genet Mol Res. 2015;14(1):1707-1717. doi:10.4238/2015.March.6.17
  21. Pardo A, Cabrera S, Maldonado M, Selman M. Role of matrix metalloproteinases in the pathogenesis of idiopathic pulmonary fibrosis. Respir Res. 2016;17(1):23.  doi:10.1186/s12931-016-0343-6
  22. Schumann C, Lepper PM, Frank H, Schneiderbauer R, Wibmer T, Kropf C, Stoiber KM, Rüdiger S, Kruska L, Krahn T, Kramer F. Circulating biomarkers of tissue remodelling in pulmonary hypertension. Biomarkers. 2010;15(6):523-532.  doi:10.3109/1354750X.2010.492431
  23. Jiang L, Zhou T, Liu H. Combined effects of the ATP-sensitive potassium channel opener pinacidil and simvastatin on pulmonary vascular remodeling in rats with monocrotaline-induced pulmonary arterial hypertension. Pharmazie. 2012;67(6):547-552.
  24. Nevzorova V, Tilik T, Gilifanov E, Panchenko E, Vakhrusheva S, Tilik V. Role of matrix metalloproteinases in forming morphofunctional imbalance of airways in case of chronic obstructive lung disease. Tichookeanskii meditsinskii zhurnal. 2011;2:9-13. (In Russ.) Available at: http://www.tmj-vgmu.ru/index.php/en/2012-03-05-10-04-41/996-2011-god-2-44
  25. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, Hanahan D. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol. 2000;2(10):737-744.
  26. Anderson TL, del Carem Ovejero M, Kirkegaard T et al. A scrutiny of matrix metalloproteinases in osteoclasts: evidence for heterogeneity and for the presence of MMPs synthesized by other cells. Bone. 2004;35:1107-1119.
  27. Li Y, Zhang Zh, Xu Yo et al. TNF-α Up-regulates Matrix Metalloproteinase-9 Expression and Activity in Alveolar Macrophages from Patients with Chronic Obstructive Pulmonary Disease. J Huazhong University of Science and Technology 2006;26(6):647-650.  doi:10.1007/s 11596-006-0604-6
  28. Song H, Cheng Y, Bi G, Zhu Y, Jun W, Ma W, Wu H. Release of Matrix Metalloproteinases-2 and 9 by S-Nitrosylated Caveolin-1 Contributes to Degradation of Extracellular Matrix in tPA-Treated Hypoxic Endothelial Cells. PLoS One. 2016;11(2):e0149269. doi:10.1371/journal.pone.0149269
  29. Safdar Z, Tamez E, Chan W, Arya B, Ge Y, Deswal A, Bozkurt B, Frost A, Entman M. Circulating collagen biomarkers as indicators of disease severity in pulmonary arterial hypertension. JACC Heart Fail. 2014;2(4):412-421.  doi:10.1016/j.jchf.2014.03.013
  30. Benza RL, Gomberg-Maitland M, Demarco T, Frost AE, Torbicki A, Langleben D, Pulido T, Correa-Jaque P, Passineau MJ, Wiener HW, Tamari M, Hirota T, Kubo M, Tiwari HK. Endothelin-1 Pathway Polymorphisms and Outcomes in Pulmonary Arterial Hypertension. Am J Respir Crit Care Med. 2015;192(11):1345-1354. doi:10.1164/rccm.201501-0196OC
  31. Serizawa K, Yogo K, Tashiro Y, Takeda S, Kawasaki R, Aizawa K, Endo K. Eldecalcitol prevents endothelial dysfunction in postmenopausal osteoporosis model rats. J Endocrinol. 2016;228(2):75-84.  doi:10.1530/JOE-15-0332
  32. Mestek ML, Weil BR, Greiner JJ, Westby CM, DeSouza CA, Stauffer BL. Osteopenia and endothelin-1-mediated vasconstrictor tone in postmenopausal women. Bone. 2010;47(3):542-545.  doi:10.1016/j.bone.2010.05.041

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.